Ocugen falls as FDA declines to authorize COVID-19 shot for children

Hanall Biopharma

04/03/2022 12:15

** Shares of biopharma co  OCGN.O  down nearly 4% at $3.16
premarket
    ** OCGN says U.S FDA has declined emergency use
authorization to its COVID-19 vaccine for individuals 2 to 18
years of age  urn:newsml:reuters.com:*:nGNX9N3N27
    ** In December, co's partner Bharat Biotech released data
from a mid-to-late stage trial of the vaccine, Covaxin, in
children in India, showing robust neutralizing antibody response
and favorable safety profile  urn:newsml:reuters.com:*:nL4N2TF211
    ** OCGN says it would continue working with FDA to determine
path forward for approval of vaccine in children
    ** The company is developing Covaxin for use in U.S. and
Canadian markets
    ** Stock down 27.7% YTD, up to last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))